Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Myelin Repair Foundation

www.myelinrepair.org

Latest From Myelin Repair Foundation

Venture Funding Deals, March 2015

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced January through February 2015.

BioPharmaceutical Medical Device

Can A New Drug Screen Crack The Code On Myelin Repair?

A new high-throughput assay developed at the University of California, San Francisco has already identified a generic over-the-counter drug that promotes remyelination. A clinical trial is soon to follow, only the second for myelin repair in multiple sclerosis.

BioPharmaceutical Medical Device

Recent Tech Transfer Deals, September 2013

Derived from Strategic Transactions, Elsevier Business Intelligence’s premium source for tracking life sciences deal activity, the Tech Transfers column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors.

BioPharmaceutical Medical Device

Bothering To Look: With New Tools, Biotech Goes Back To The Black Box

For decades drug discovery meant testing new compounds in cells and animals without knowing how or why they might work. A shift to reductionist, target-based discovery has done little to nothing to bring more drugs to market. Proponents say it’s time for more phenotypic inquiry early in the drug discovery process, bolstered when possible by better tools and technology.

BioPharmaceutical North America
See All
Advertisement
Advertisement
UsernamePublicRestriction

Register